LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Начало・Списък с акции・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Отворен

4.45 1.14

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.36

Максимум

4.46

Ключови измерители
By Trading Economics
Приходи	27M 2.5M
Продажби	9M 11M
Марж на печалбата	23.494
Служители	44
EBITDA	27M 2.6M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	210M 849M
Предишно отваряне	3.31
Предишно затваряне	4.45

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

3.255 / 3.365 Подкрепа & съпротива

Arbutus Biopharma Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.09.2025 г., 18:25 ч. UTC

Значими двигатели на пазара

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28.09.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28.09.2025 г., 23:48 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.09.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28.09.2025 г., 23:34 ч. UTC

Пазарно говорене

Oil Falls on Likely Technical Correction -- Market Talk

27.09.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

26.09.2025 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26.09.2025 г., 20:54 ч. UTC

Печалби

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

26.09.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26.09.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

26.09.2025 г., 19:54 ч. UTC

Пазарно говорене

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26.09.2025 г., 19:53 ч. UTC

Придобивния, сливания и поглъщания

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26.09.2025 г., 19:40 ч. UTC

Печалби

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26.09.2025 г., 19:24 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26.09.2025 г., 19:17 ч. UTC

Пазарно говорене

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26.09.2025 г., 19:15 ч. UTC

Пазарно говорене

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

26.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26.09.2025 г., 18:50 ч. UTC

Пазарно говорене

Печалби

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26.09.2025 г., 18:36 ч. UTC

Пазарно говорене

Silver Closes Out Week With Strong Surge -- Market Talk

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: Global Development Hasn't Received All Necessary Approvals >ING

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26.09.2025 г., 17:54 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26.09.2025 г., 16:56 ч. UTC

Пазарно говорене

Печалби

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26.09.2025 г., 16:41 ч. UTC

Пазарно говорене

Печалби

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26.09.2025 г., 16:26 ч. UTC

Печалби

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arbutus Biopharma Corp Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Arbutus Biopharma Corp през последните 3 месеца.

Техническа оценка

By Trading Central

3.255 / 3.365Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.